8,800 Shares in ANI Pharmaceuticals, Inc. $ANIP Acquired by LSV Asset Management

LSV Asset Management purchased a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 8,800 shares of the specialty pharmaceutical company’s stock, valued at approximately $695,000.

A number of other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in ANI Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after acquiring an additional 27,598 shares during the last quarter. UBS Group AG increased its stake in ANI Pharmaceuticals by 45.8% in the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after acquiring an additional 185,172 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in ANI Pharmaceuticals in the 3rd quarter worth approximately $32,992,000. Rubric Capital Management LP increased its stake in ANI Pharmaceuticals by 33.3% in the 3rd quarter. Rubric Capital Management LP now owns 343,414 shares of the specialty pharmaceutical company’s stock worth $31,457,000 after acquiring an additional 85,745 shares during the last quarter. Finally, Balyasny Asset Management L.P. increased its stake in ANI Pharmaceuticals by 2,785.7% in the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock worth $26,211,000 after acquiring an additional 276,233 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

Insider Transactions at ANI Pharmaceuticals

In other news, insider Christopher Mutz sold 3,162 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $71.64, for a total value of $226,525.68. Following the completion of the transaction, the insider owned 91,309 shares in the company, valued at approximately $6,541,376.76. The trade was a 3.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Thomas Andrew Rowland sold 4,772 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $74.91, for a total value of $357,470.52. Following the completion of the transaction, the senior vice president owned 38,730 shares of the company’s stock, valued at approximately $2,901,264.30. This trade represents a 10.97% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 91,427 shares of company stock worth $7,089,066. 8.10% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Price Performance

Shares of ANI Pharmaceuticals stock opened at $81.76 on Thursday. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of 20.70 and a beta of 0.46. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. The stock has a 50 day moving average price of $78.51 and a 200-day moving average price of $79.79. ANI Pharmaceuticals, Inc. has a one year low of $57.33 and a one year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. The firm had revenue of $237.46 million during the quarter, compared to analysts’ expectations of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company’s quarterly revenue was up 20.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities analysts expect that ANI Pharmaceuticals, Inc. will post 7.73 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ANIP. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Five research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.